Who makes Alflibercept?

Alflibercept is developed by Southeast Retina Center, Georgia.

What development phase is Alflibercept in?

Alflibercept is FDA-approved (marketed).

Last reviewed 2026-04-19 · How we verify

Alflibercept

Southeast Retina Center, Georgia · FDA-approved active Small molecule

At a glance

Generic name	Alflibercept
Also known as	Eylea
Sponsor	Southeast Retina Center, Georgia
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

IAI for Persistent DME After Treatment With Bevacizumab And Ranibizumab (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Alflibercept CI brief — competitive landscape report
Alflibercept updates RSS · CI watch RSS
Southeast Retina Center, Georgia portfolio CI